Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.

den Broeder N, Verhoef L, de Man YA, Kok MR, Thurlings R, van der Weele W, van den Bemt BJ, van den Hoogen FH, van der Maas A, den Broeder AA

Open source

DOI
10.1136/rmdopen-2023-003659
Published
2024 Apr 9
Container
RMD open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/rmdopen-2023-003659,
  title = {Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.},
  author = {den Broeder N and Verhoef L and de Man YA and Kok MR and Thurlings R and van der Weele W and van den Bemt BJ and van den Hoogen FH and van der Maas A and den Broeder AA},
  year = {2024},
  journal = {RMD open},
  doi = {10.1136/rmdopen-2023-003659},
  url = {https://doi.org/10.1136/rmdopen-2023-003659}
}

RIS

TY  - JOUR
TI  - Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.
AU  - den Broeder N
AU  - Verhoef L
AU  - de Man YA
AU  - Kok MR
AU  - Thurlings R
AU  - van der Weele W
AU  - van den Bemt BJ
AU  - van den Hoogen FH
AU  - van der Maas A
AU  - den Broeder AA
PY  - 2024
JO  - RMD open
DO  - 10.1136/rmdopen-2023-003659
UR  - https://doi.org/10.1136/rmdopen-2023-003659
ER  - 

APA

N, D. B., L, V., YA, D. M., MR, K., R, T., W, V. D. W., BJ, V. D. B., FH, V. D. H., A, V. D. M., & AA, D. B. (2024). Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.. RMD open. https://doi.org/10.1136/rmdopen-2023-003659

Source records